Overview
A modified IGF-1 that hangs around 20–30× longer than the regular version. Used by athletes for sustained growth signaling.
What It Does
Long-acting IGF-1 analog (20–30 hr half-life), drives muscle protein synthesis and cellular repair directly. Binds IGF-1R with high affinity. Activates PI3K/Akt/mTOR for protein synthesis.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 0.1 mg | + 0.2 mL acetic acid | 0.5 mg/mL |
| 1 mg | + 2 mL acetic acid | 0.5 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Standard | Daily post-workout | 50 mcg | Systemic dose. |
| Site IM | Post-workout | 25–40 mcg/site | Local muscle. |
| Off | Equal to on-time | – | Mandatory. |
4–6 weeks on, equal time off. Off periods critical, receptor desensitises permanently if skipped.
With food, post-workout; long half-life means hypoglycemia risk all day.
LR3 is not FDA-approved in any form (mecasermin ≠ LR3); no human dosing data.
Direct IGF-1 bypasses GH, so estrogen doesn’t soften it; same growth-signal caution: breast, ovarian, or uterine history. Men: Same growth-signal caution, prostate; watch PSA in men over Direct IGF-1 bypasses GH, so estrogen doesn’t soften it; same growth-signal caution: breast, ovarian, or uterine history. Men: Same growth-signal caution, prostate; watch PSA in men over ~40.
Handling & Stacking
- Muscle fullness within days, recovery by 2–4 wks.
- Hypoglycaemia risk, keep fast carbs handy; off-cycles mandatory.
- Supply math 0.1mg → 14 vials | 1mg → 2 vials (4-wk @ 50 mcg × 7/wk)
Safety & Patient Education
- Intracranial hypertension with somatropin (papilledema, vision changes, headache, nausea, vomiting) Insulin resistance and new-onset T2DM Fluid retention, edema, carpal tunnel Pancreatitis (rare) IGF-1 elevation above age range carries theoretical malignancy risk 20–30 hour half-life means hypoglycemia risk extends throughout the day.
- Long-term IGF-1 elevation theoretical malignancy concern.
- IGF-1 (baseline / Wk 8 / end; you're dosing it directly, so this tracks exposure), Fasting glucose (Wk 0/4/8) Lipid panel (Wk 0/12) Hip/scoliosis exam in pediatrics Out of range?
- IGF-1 above your age range = too much growth signal → drop the dose.
- Hypoglycemia is the real acute risk and LR3's long half-life drags it out for hours – dose with food/carbs, keep fast sugar handy; shaky, sweaty, or foggy = treat it right away.
